Developer docs
API playgroundTry for free, no card

Search company profiles

VaxThera

Full company profile

uuid000rtli

Namestring
VaxThera
Legal namestring
VaxThera S.A.S.
Websiteurl
vaxthera.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

VaxThera is a Colombian biotechnology company founded in 2021 that designs, develops, and manufactures human and veterinary vaccines, with a stated mission to restore domestic vaccine production for Colombia after more than 20 years of import dependence. The company operates two technology platforms — an mRNA platform anchored on Quantoom Technologies' Ntensify™ automated cell-free production system, and an MVA viral vector platform — and offers fill-and-finish contract manufacturing services for third-party vaccine producers. Its pipeline includes the USPTO-patented UniVax universal COVID-19 vaccine (mosaic antigen design), vaccines in development against Zika, Chikungunya, and Yellow Fever, and a Personalized Prevention Program (PPP) delivered through insurance partners that addresses adult vaccination gaps outside the government-funded Expanded Immunization Program (PAI). The most material commercial initiative to date is the September 2025 launch of a region-leading HPV prevention program (Gardasil 9®) with parent company Seguros SURA, targeting more than 50,000 doses across six Colombian cities.

The company is organized across three legal entities: VaxThera S.A.S. in Medellín (commercial and R&D headquarters), VaxThera Zona Franca S.A.S. in Rionegro (the 35,000 m² LEED Gold-certified manufacturing plant, Phase 1 capacity of 100+ million doses annually, scaling to 200–300 million in Phase 2), and VaxThera LLC in Madison, Wisconsin (R&D and scientific collaboration with the University of Wisconsin-Madison). The R&D footprint includes an 820 m² research laboratory equipped with mRNA and viral-vector capabilities.

VaxThera is a wholly-owned subsidiary of Seguros SURA Colombia (part of Grupo SURA), which has committed approximately $100 million USD across plant construction, R&D capabilities, and talent acquisition. Revenue is generated through institutional channels: B2B sales to the Colombian government (PAI), B2B2C partnerships with insurance providers (SURA), contract fill-and-finish services for third-party vaccine producers, and technology transfer/licensing agreements with international partners including Gennova (India), Instituto Butantan (Brazil), and Univercells (Belgium). GMP certification processes are concurrently underway with INVIMA, COFEPRIS, FDA, and EMA, signaling an explicit export orientation. Current headcount of 11–50 is projected to scale to 500+ within five years as commercial production comes online.

Short descriptiontext

VaxThera is a Colombian biotechnology company founded in 2021 that develops and manufactures human and veterinary vaccines using mRNA and MVA viral-vector platforms, and operates a 100+ million dose fill-and-finish plant in Rionegro. It serves Colombian government health programs, insurance partners (Seguros SURA), and regional LATAM markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRionegro, Colombia
HQ citystring
Rionegro
HQ countrystring
Colombia
HQ regionstring
Latin America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccine development, biologics manufacturing, mRNA technology, viral vector platforms, fill-and-finish services
Industry4 codes
PRIMARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines
SECONDARYBPADAIAB
Immunization & Vaccine Delivery Programs
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Vaccine Manufacturing and Biologics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Vaccine Manufacturing and Sales
TypeHardware Sales
Description

VaxThera manufactures and sells vaccines domestically and regionally, including products for the Expanded Immunization Program (PAI) such as HPV, Pentavalent, Pneumococcal, Influenza, Polio, and Rotavirus vaccines. Production capacity exceeds 100 million annual doses.

vaxthera.com
2Personalized Prevention Programs (PPP)
TypeProfessional Services
Description

B2B2C vaccination programs offered in partnership with insurance companies like SURA, providing preventive healthcare services to policyholders. Programs target diseases like HPV and influenza.

vaxthera.com
3Technology Transfer and Licensing
TypeLicensing Royalties
Description

Co-development and technology transfer partnerships with international pharmaceutical companies for vaccine production in Latin America, including agreements with companies from India, USA, Europe, and Latin America.

vaxthera.com
4Contract Manufacturing
TypeManaged Services
Description

Fill-and-finish services for third-party vaccine products, leveraging state-of-the-art facilities and GMP compliance.

vaxthera.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Personalized Prevention Program (PPP) - Free vaccination for SURA policyholders
ModelSubscriptionBilling cadenceMulti-year contract
Notes

The HPV vaccination program is provided at no cost to eligible SURA health insurance or life insurance policyholders as part of the company's preventive health initiative.

vaxthera.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

VaxThera is a Colombian biotechnology company that researches, develops, and manufactures human and veterinary vaccines and biological products using mRNA and MVA viral vector technology platforms. It operates a 35,000 m² LEED Gold-certified manufacturing plant in Rionegro, Antioquia with capacity for more than 100 million doses per year, providing fill-and-finish contract manufacturing services and producing vaccines for the Expanded Immunization Program (PAI), HPV, Pentavalent, Pneumococcal, Influenza, Polio, and Rotavirus. The company also delivers Personalized Prevention Programs (PPP) — including the largest HPV prevention program in Latin America in partnership with Seguros SURA — targeting adult populations aged 18-59 outside the standard immunization schedule.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100 million+ doses annual production capacity
+3 more records
Product overview1 text field

VaxThera is a Colombian biotechnology company developing a diversified portfolio of human and veterinary vaccines alongside contract manufacturing services. Core products include UniVax (universal COVID-19 vaccine) and vaccines in pipeline targeting Zika, Chikungunya, and Yellow Fever. The company operates two technology platforms (mRNA and viral vector) and offers fill-and-finish manufacturing services with capacity of 100 million doses annually. Healthcare services include Personalized Prevention Programs (PPP) for adult vaccination and large-scale HPV prevention programs. VaxThera S.A.S. (Medellín) handles research and commercialization, VaxThera Zona Franca S.A.S. (Rionegro) manages production, and VaxThera LLC (Wisconsin, USA) focuses on R&D.

Product and service1 record
1Fill-and-Finish Manufacturing Services
CategoryContract manufacturing services for vaccines and biologics Vaccination program — HPV prevention Personalized preventive healthcare services
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Ministerio de Salud y Protección Social de Colombia
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-28
Description

Convenio Marco Especial de Cooperación Científica y Tecnológica between Minsalud, INS, and VaxThera to strengthen local capabilities in biological research, development, and production for health sovereignty. Includes researcher exchange, joint project formulation, technology transfer, and identification of priority biologics for local production.

vaxthera.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-28
Description

Strategic partnership for cooperation in scientific, technical, and technological development of biologics and health technologies. Aims to strengthen local capacity for public health emergency response and establish long-term health sovereignty for Colombia.

Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2024-05-01
Description

Collaboration agreement for vaccine development using viral vector and mRNA platforms with state-of-the-art automated equipment. This partnership represents VaxThera's route to production and is part of the company's strategic manufacturing capabilities.

4Instituto Butantan (Brazil)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

Memorandum of understanding for bilateral technology transfer for vaccine production. Butantan is the largest vaccine and serum producer in Latin America, responsible for most immunobiological production in Brazil including 100% of influenza vaccines for Brazil's National Immunization Campaign.

vaxthera.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Academic partnership for vaccine research and development, including joint work on Zika, Chikungunya, and Yellow Fever vaccines under co-financing from Colombia's Ministry of Science, Technology and Innovation.

Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2023-01-01
Description

Acquisition of unique Ntensify™ system equipment in Colombia and Latin America for automated, cell-free mRNA vaccine production technology. This equipment enables more efficient, higher quality, and safer vaccine production.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Funding partnership for veterinary COVID-19 vaccine development with University of Wisconsin-Madison to evaluate UniVax for limiting virus transmission across multiple animal species and reducing zoonotic transmission risk to humans.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-06-10
Description

Long-term alliance for mRNA and other biological products technology. Initial phase includes commercialization of Gennova products in Colombia and Latin America, with joint efforts to strengthen technology experience and scientific resource management for local vaccine and biologic production capabilities.

9Universidad de Wisconsin-Madison (USA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Founding scientific partner providing expertise in vaccine development. Founder Dr. Jorge Emilio Osorio serves as professor at the university, and the company maintains R&D operations in Wisconsin. Collaborative research on emerging infectious diseases including COVID-19, Zika, Chikungunya, and Yellow Fever.

vaxthera.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic ally for scientific research, talent development, and vaccine development programs.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Instituto Butantan
TypeDirect peer
Description

Latin America's largest vaccine and serum producer (100% of Brazil's influenza PNI supply) and a signed VaxThera technology-transfer partner. Comparable in mandate (public-sector vaccine sovereignty), scale of domestic production, and pipeline scope across tropical diseases.

TypeDirect peer
Description

Indian mRNA technology partner with a long-term alliance for biological products commercialization in LATAM. Comparable as an emerging-market biologics manufacturer developing mRNA and other biologics with technology-transfer-driven growth.

TypeDirect peer
Description

India-headquartered vaccine developer with a diversified human vaccine portfolio including viral and emerging-disease candidates (rotavirus, chikungunya). Comparable in multi-platform vaccine strategy, emerging-market focus, and contract manufacturing for governments.

4Biological E
TypeEmerging player
Description

Indian vaccine manufacturer with large-scale fill-finish capacity and PAI-relevant pediatric vaccines (Pentavalent, Pneumococcal). Comparable in targeting emerging-market immunization tenders at scale.

5Sinovac Biotech
TypeEmerging player
Description

China-based vaccine producer with broad pediatric portfolio (including COVID-19 and influenza) and significant emerging-market exports. Comparable in operating model of government-aligned regional vaccine production.

TypeBroad incumbent
Description

Global mRNA platform incumbent with deep R&D pipeline and large commercial scale. Relevant as the benchmark for the mRNA platform VaxThera is deploying via Quantoom's Ntensify system.

TypeEmerging player
Description

Earlier-stage mRNA company with a platform spanning prophylactic vaccines and oncology. Comparable as an mRNA platform developer commercializing through technology partnerships rather than solely direct sales.

8Sanofi Pasteur
TypeBroad incumbent
Description

Global vaccine incumbent with broad pediatric and adult portfolio. Comparable as a competing supplier to LATAM immunization programs and a reference point for the PAI antigens VaxThera plans to produce domestically.

TypeBroad incumbent
Description

Global vaccine major with extensive pediatric and adult immunization portfolio. Competes for the same PAHO/WHO procurement contracts that VaxThera would target regionally.

TypeOthers
Description

Belgian technology provider of the Ntensify cell-free mRNA production system that VaxThera has deployed. Comparable as an enabler/ecosystem participant supporting VaxThera's manufacturing platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VaxThera

Vaccine Manufacturing and Biologicsvaxthera.com

VaxThera is a Colombian biotechnology company founded in 2021 that develops and manufactures human and veterinary vaccines using mRNA and MVA viral-vector platforms, and operates a 100+ million dose fill-and-finish plant in Rionegro. It serves Colombian government health programs, insurance partners (Seguros SURA), and regional LATAM markets.

What VaxThera does

VaxThera is a Colombian biotechnology company founded in 2021 that designs, develops, and manufactures human and veterinary vaccines, with a stated mission to restore domestic vaccine production for Colombia after more than 20 years of import dependence. The company operates two technology platforms — an mRNA platform anchored on Quantoom Technologies' Ntensify™ automated cell-free production system, and an MVA viral vector platform — and offers fill-and-finish contract manufacturing services for third-party vaccine producers. Its pipeline includes the USPTO-patented UniVax universal COVID-19 vaccine (mosaic antigen design), vaccines in development against Zika, Chikungunya, and Yellow Fever, and a Personalized Prevention Program (PPP) delivered through insurance partners that addresses adult vaccination gaps outside the government-funded Expanded Immunization Program (PAI). The most material commercial initiative to date is the September 2025 launch of a region-leading HPV prevention program (Gardasil 9®) with parent company Seguros SURA, targeting more than 50,000 doses across six Colombian cities.

The company is organized across three legal entities: VaxThera S.A.S. in Medellín (commercial and R&D headquarters), VaxThera Zona Franca S.A.S. in Rionegro (the 35,000 m² LEED Gold-certified manufacturing plant, Phase 1 capacity of 100+ million doses annually, scaling to 200–300 million in Phase 2), and VaxThera LLC in Madison, Wisconsin (R&D and scientific collaboration with the University of Wisconsin-Madison). The R&D footprint includes an 820 m² research laboratory equipped with mRNA and viral-vector capabilities.

VaxThera is a wholly-owned subsidiary of Seguros SURA Colombia (part of Grupo SURA), which has committed approximately $100 million USD across plant construction, R&D capabilities, and talent acquisition. Revenue is generated through institutional channels: B2B sales to the Colombian government (PAI), B2B2C partnerships with insurance providers (SURA), contract fill-and-finish services for third-party vaccine producers, and technology transfer/licensing agreements with international partners including Gennova (India), Instituto Butantan (Brazil), and Univercells (Belgium). GMP certification processes are concurrently underway with INVIMA, COFEPRIS, FDA, and EMA, signaling an explicit export orientation. Current headcount of 11–50 is projected to scale to 500+ within five years as commercial production comes online.

VaxThera firmographics

Firmographics
Name
VaxThera
Legal name
VaxThera S.A.S.
Website
https://vaxthera.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
101–250 employees
Short description
VaxThera is a Colombian biotechnology company founded in 2021 that develops and manufactures human and veterinary vaccines using mRNA and MVA viral-vector platforms, and operates a 100+ million dose fill-and-finish plant in Rionegro. It serves Colombian government health programs, insurance partners (Seguros SURA), and regional LATAM markets.
Ownership category
akta.pro rank

VaxThera industry classification

Industry
Product category
Vaccine Manufacturing and Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines
SECONDARYBPADAIAB
Immunization & Vaccine Delivery Programs

Keywords

  • Vaccine development
  • Biologics manufacturing
  • MRNA technology
  • Viral vector platforms
  • Fill-and-finish services

Where VaxThera is headquartered

Location

Headquarters

HQ city
Rionegro
HQ country
Colombia
HQ region
Latin America

Offices4 records

Markets served

VaxThera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Vaccine Manufacturing and Sales: VaxThera manufactures and sells vaccines domestically and regionally, including products for the Expanded Immunization Program (PAI) such as HPV, Pentavalent, Pneumococcal, Influenza, Polio, and Rotavirus vaccines. Production capacity exceeds 100 million annual doses.
  2. Personalized Prevention Programs (PPP): B2B2C vaccination programs offered in partnership with insurance companies like SURA, providing preventive healthcare services to policyholders. Programs target diseases like HPV and influenza.
  3. Technology Transfer and Licensing: Co-development and technology transfer partnerships with international pharmaceutical companies for vaccine production in Latin America, including agreements with companies from India, USA, Europe, and Latin America.
  4. Contract Manufacturing: Fill-and-finish services for third-party vaccine products, leveraging state-of-the-art facilities and GMP compliance.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractPersonalized Prevention Program (PPP) - Free vaccination for SURA policyholders

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

VaxThera product offering

Product offering

Core offering

VaxThera is a Colombian biotechnology company that researches, develops, and manufactures human and veterinary vaccines and biological products using mRNA and MVA viral vector technology platforms. It operates a 35,000 m² LEED Gold-certified manufacturing plant in Rionegro, Antioquia with capacity for more than 100 million doses per year, providing fill-and-finish contract manufacturing services and producing vaccines for the Expanded Immunization Program (PAI), HPV, Pentavalent, Pneumococcal, Influenza, Polio, and Rotavirus. The company also delivers Personalized Prevention Programs (PPP) — including the largest HPV prevention program in Latin America in partnership with Seguros SURA — targeting adult populations aged 18-59 outside the standard immunization schedule.

Product overview

VaxThera is a Colombian biotechnology company developing a diversified portfolio of human and veterinary vaccines alongside contract manufacturing services. Core products include UniVax (universal COVID-19 vaccine) and vaccines in pipeline targeting Zika, Chikungunya, and Yellow Fever. The company operates two technology platforms (mRNA and viral vector) and offers fill-and-finish manufacturing services with capacity of 100 million doses annually. Healthcare services include Personalized Prevention Programs (PPP) for adult vaccination and large-scale HPV prevention programs. VaxThera S.A.S. (Medellín) handles research and commercialization, VaxThera Zona Franca S.A.S. (Rionegro) manages production, and VaxThera LLC (Wisconsin, USA) focuses on R&D.

Differentiator

Problem solved

Functional benefit

Products and services

  • Fill-and-Finish Manufacturing Services

Quantifiable outcome

  • 100 million+ doses annual production capacity
  • +3 more outcomes

Companies that use VaxThera

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

VaxThera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

VaxThera partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and flagship.

  • Ministerio de Salud y Protección Social de ColombiacoreStrategic or Co-development Partner · 28 February 2025Convenio Marco Especial de Cooperación Científica y Tecnológica between Minsalud, INS, and VaxThera to strengthen local capabilities in biological research, development, and production for health sovereignty. Includes researcher exchange, joint project formulation, technology transfer, and identification of priority biologics for local production.
  • Instituto Nacional de Salud (INS)coreStrategic or Co-development Partner · 28 February 2025Strategic partnership for cooperation in scientific, technical, and technological development of biologics and health technologies. Aims to strengthen local capacity for public health emergency response and establish long-term health sovereignty for Colombia.
  • Univercells (Belgium)flagshipTechnology or Integration · 1 May 2024Collaboration agreement for vaccine development using viral vector and mRNA platforms with state-of-the-art automated equipment. This partnership represents VaxThera's route to production and is part of the company's strategic manufacturing capabilities.
  • Instituto Butantan (Brazil)coreStrategic or Co-development Partner · 1 June 2023Memorandum of understanding for bilateral technology transfer for vaccine production. Butantan is the largest vaccine and serum producer in Latin America, responsible for most immunobiological production in Brazil including 100% of influenza vaccines for Brazil's National Immunization Campaign.
  • Universidad Nacional de ColombiacoreStrategic or Co-development Partner · 1 January 2023Academic partnership for vaccine research and development, including joint work on Zika, Chikungunya, and Yellow Fever vaccines under co-financing from Colombia's Ministry of Science, Technology and Innovation.
  • Quantoom Technologies (Ntensify™ System)flagshipTechnology or Integration · 1 January 2023Acquisition of unique Ntensify™ system equipment in Colombia and Latin America for automated, cell-free mRNA vaccine production technology. This equipment enables more efficient, higher quality, and safer vaccine production.
  • USDA - United States Department of AgriculturecoreStrategic or Co-development Partner · 1 January 2023Funding partnership for veterinary COVID-19 vaccine development with University of Wisconsin-Madison to evaluate UniVax for limiting virus transmission across multiple animal species and reducing zoonotic transmission risk to humans.
  • Gennova Biopharmaceuticals (India)coreTechnology or Integration · 10 June 2022Long-term alliance for mRNA and other biological products technology. Initial phase includes commercialization of Gennova products in Colombia and Latin America, with joint efforts to strengthen technology experience and scientific resource management for local vaccine and biologic production capabilities.
  • Universidad de Wisconsin-Madison (USA)coreStrategic or Co-development Partner · 1 January 2021Founding scientific partner providing expertise in vaccine development. Founder Dr. Jorge Emilio Osorio serves as professor at the university, and the company maintains R&D operations in Wisconsin. Collaborative research on emerging infectious diseases including COVID-19, Zika, Chikungunya, and Yellow Fever.
  • Universidad Nacional de ColombiacoreStrategic or Co-development PartnerAcademic ally for scientific research, talent development, and vaccine development programs.

Scale indicators10 records

Recent moves12 records

Expansion highlights7 records

VaxThera competitors and assessment

Company assessment

Direct peers

  • Instituto Butantan: Latin America's largest vaccine and serum producer (100% of Brazil's influenza PNI supply) and a signed VaxThera technology-transfer partner. Comparable in mandate (public-sector vaccine sovereignty), scale of domestic production, and pipeline scope across tropical diseases.
  • Gennova Biopharmaceuticals: Indian mRNA technology partner with a long-term alliance for biological products commercialization in LATAM. Comparable as an emerging-market biologics manufacturer developing mRNA and other biologics with technology-transfer-driven growth.
  • Bharat Biotech: India-headquartered vaccine developer with a diversified human vaccine portfolio including viral and emerging-disease candidates (rotavirus, chikungunya). Comparable in multi-platform vaccine strategy, emerging-market focus, and contract manufacturing for governments.

Emerging players

  • Biological E: Indian vaccine manufacturer with large-scale fill-finish capacity and PAI-relevant pediatric vaccines (Pentavalent, Pneumococcal). Comparable in targeting emerging-market immunization tenders at scale.
  • Sinovac Biotech: China-based vaccine producer with broad pediatric portfolio (including COVID-19 and influenza) and significant emerging-market exports. Comparable in operating model of government-aligned regional vaccine production.
  • CureVac: Earlier-stage mRNA company with a platform spanning prophylactic vaccines and oncology. Comparable as an mRNA platform developer commercializing through technology partnerships rather than solely direct sales.

Broad incumbents

  • Moderna: Global mRNA platform incumbent with deep R&D pipeline and large commercial scale. Relevant as the benchmark for the mRNA platform VaxThera is deploying via Quantoom's Ntensify system.
  • Sanofi Pasteur: Global vaccine incumbent with broad pediatric and adult portfolio. Comparable as a competing supplier to LATAM immunization programs and a reference point for the PAI antigens VaxThera plans to produce domestically.
  • GSK Vaccines: Global vaccine major with extensive pediatric and adult immunization portfolio. Competes for the same PAHO/WHO procurement contracts that VaxThera would target regionally.

Others

  • Quantoom Biosciences: Belgian technology provider of the Ntensify cell-free mRNA production system that VaxThera has deployed. Comparable as an enabler/ecosystem participant supporting VaxThera's manufacturing platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VaxThera social profiles

Digital presence

VaxThera compliance and trust

Trust signal

Compliance5 records

VaxThera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VaxThera leadership team

Management profile

Number of profiles

Profiles9 records

VaxThera subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

VaxThera funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VaxThera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VaxThera

What does VaxThera do?

VaxThera is a Colombian biotechnology company that researches, develops, and manufactures human and veterinary vaccines and biological products using mRNA and MVA viral vector technology platforms. It operates a 35,000 m² LEED Gold-certified manufacturing plant in Rionegro, Antioquia with capacity for more than 100 million doses per year, providing fill-and-finish contract manufacturing services and producing vaccines for the Expanded Immunization Program (PAI), HPV, Pentavalent, Pneumococcal, Influenza, Polio, and Rotavirus. The company also delivers Personalized Prevention Programs (PPP) — including the largest HPV prevention program in Latin America in partnership with Seguros SURA — targeting adult populations aged 18-59 outside the standard immunization schedule.

Is VaxThera a public or private company?

VaxThera is a private company. It is classified as corporate owned and is currently operating.

When was VaxThera founded?

VaxThera was founded in 2021. It employs 101 to 250 people.

Where is VaxThera based?

VaxThera is headquartered in Rionegro, Colombia, in the Latin America region.

How does VaxThera make money?

Four revenue lines are on record. Vaccine Manufacturing and Sales are the primary driver. The others are personalized Prevention Programs (PPP), technology Transfer and Licensing and contract Manufacturing.

Who are VaxThera's main competitors?

Direct peers on record are Instituto Butantan, Gennova Biopharmaceuticals and Bharat Biotech. Emerging players are Biological E, Sinovac Biotech and CureVac. Broad incumbents are Moderna, Sanofi Pasteur and GSK Vaccines. Quantoom Biosciences is listed as an others.

Does VaxThera have an API?

No public API is recorded for VaxThera.

What industry is VaxThera in?

VaxThera's product category is Vaccine Manufacturing and Biologics. Its primary akta.pro industry code is HLAMAKAH, Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA), with a secondary code of HLAAAEAK, Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Portafolio.coVaxThera proyecta producir hasta 700 millones de dosis de vacunas en Colombia ante futuras emergencias sanitariasVaxThera plans to expand its vaccine production capacity to 250 million doses annually, reaching 600-700 million in emergencies, backed by European funding and international alliances. The company signed agreements with India, South Korea, the US, and Europe in 2026, including a partnership with Serum Institute of India. The initiative aims to strengthen Colombia's regional health autonomy.NaverGC Biopharma Signs $39.5 Million Flu Vaccine Supply Deal With Colombia’s VaxTheraGC Biopharma signed a $39.5 million agreement with Colombia's VaxThera to supply bulk influenza vaccine and provide technical support for production. VaxThera will handle filling, packaging, and quality control, while GC Biopharma supplies the bulk material and training. The deal supports Colombia's vaccine self-sufficiency goals and is part of a global health initiative.MkGC Biopharma to supply $44mn flu vaccine bulk to Colombia’s VaxTheraGC Biopharma signed a $44 million contract with Colombia's VaxThera to supply influenza vaccine bulk and provide production technology support. The deal includes process technology and on-site training, with VaxThera handling filling, packaging, and sales. GC Biopharma expects locally manufactured vaccines to benefit from expedited regulatory reviews and preferential procurement.NaverGC Biopharma to supply $44mn flu vaccine bulk to Colombia’s VaxTheraGC Biopharma signed an agreement with Colombia's VaxThera to supply bulk for its GC Flu vaccine and provide technical support for local production. VaxThera will handle filling, packaging, and quality control, while GC Biopharma supplies bulk and training. The deal aims to strengthen Latin America's vaccine supply chain, with GC Flu prequalified by the WHO.The future of tradingGC Biopharma to supply $44mn flu vaccine bulk to Colombia’s VaxTheraGC Biopharma signed a 59.2 billion won ($44 million) contract with Colombia's VaxThera to supply bulk influenza vaccine and provide production technology support. VaxThera will handle filling, packaging, quality control, and sales, while GC Biopharma supplies bulk and training. The deal aims to strengthen Latin America's vaccine production and self-sufficiency.BusinesskoreaGC Biopharma Signs VaxThera Vaccine DealGC Biopharma signed a contract with Colombian vaccine firm VaxThera on Nov. 2 for technical support and bulk drug supply for its GCFLU influenza vaccine. The deal, valued at about KRW 59.2 billion ($42.95 million), is backed by the RIGHT Foundation and aims to build a sustainable Latin American supply structure.Naver녹십자 수주공시 - 독감백신 공급계약 591.6억원 (매출액대비 2.97 %)Nucleus announced a flu vaccine supply contract with VaxThera Zona Franca S.A.S. for 591.6 billion won, about 2.97% of its 1.99 trillion won revenue. The 10-year deal runs from October 30, 2026 to October 30, 2036.LarepublicaVaxThera recibió préstamo del Banco Europeo de Inversiones y la Comisión Europea para vacunasVaxThera received a $17 million loan from the European Investment Bank and the European Commission for vaccine production. The funding supports building an integrated manufacturing plant in Colombia, enabling production of up to 250 million doses annually. The company aims to strengthen regional vaccine supply and prepare for future health emergencies.DevdiscourseColombia Bets on Vaccine Manufacturing to Build Health Security and Cut Import DependenceColombia is expanding domestic vaccine manufacturing through a €15 million EIB loan to VaxThera, the first tranche of a €35 million package. The expansion could produce up to 250 million doses annually, aiming to reduce import dependence and build health security. Success depends on regulatory approvals and commercial sustainability.DevdiscourseColombia Gets €15 Million Boost to Build Vaccine Capacity and Cut Import DependenceColombia received a €15 million venture loan from the EIB to boost vaccine production capacity, with a €35 million package. The funding supports VaxThera's facility expansion, enabling up to 250 million doses annually and reducing import dependence. The project also includes €1.5 million for R&D on three vaccine candidates.